23:57 , Mar 1, 2018 |  BC Extra  |  Company News

Management tracks: Alkermes, Helsinn

Neurology company Alkermes plc (NASDAQ:ALKS) hired James Robinson as president and COO. He was president of Americas operations at the Astellas US LLC unit of Astellas Pharma Inc. (Tokyo:4503). Helsinn Therapeutics Inc., a U.S. subsidiary...
23:48 , Aug 22, 2017 |  BC Extra  |  Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
00:25 , Jun 21, 2017 |  BC Extra  |  Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI)...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Financial News

Blade Therapeutics completes venture financing

Blade Therapeutics Inc. , South San Francisco, Calif.   Business: Pulmonary, Autoimmune   Date completed: 2016-06-16   Type: Venture financing   Raised: $45 million   Investors: Deerfield Management; Pfizer Venture Investments; Novartis Institute for Biomedical...
00:32 , Jun 17, 2016 |  BC Extra  |  Financial News

Fibrotic disease company Blade raises $45M

Anti-fibrotic play Blade Therapeutics Inc. (South San Francisco, Calif.) raised $45 million in a series B round led by new investor Deerfield. New investors Pfizer Venture Investments, the Novartis Institutes for Biomedical Research (NIBR) and...